MediPharm Labs Corp.

LABS

CA58504D1006

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
0.075 ^CAD	0.00%		-6.25%	+15.38%

26/06	Transcript : MediPharm Labs Corp. - Shareholder/Analyst Call
20/06	MediPharm Labs Acquires Rights for Advanced Medical Cannabis Products From Remidose Aerosols	MT

MediPharm Labs Corp. Signs New Cannabis Oil Agreements and Completes First Shipments of Supply in December 2018

January 17, 2019 at 12:00 am IST

MediPharm Labs Corp. announced it has signed three cannabis oil sales agreements, subsequent to the company’s receipt of its sales license from Health Canada on November 9, 2018. The first large shipments of cannabis oil supply left the Company’s dock in December 2018 and were aggregately valued at over $10 million.

Latest news about MediPharm Labs Corp.

Transcript : MediPharm Labs Corp. - Shareholder/Analyst Call	26/06
MediPharm Labs Acquires Rights for Advanced Medical Cannabis Products From Remidose Aerosols	20/06	MT
MediPharm Labs to Acquire Rights for Advanced Medical Cannabis Products From Remidose Aerosols	20/06	MT
MediPharm Labs Corp. Brief: Acquiring Advanced Medical Cannabis Delivery Method Technology from Remidose Aerosols	20/06	MT
Transcript : MediPharm Labs Corp., Q1 2024 Earnings Call, May 15, 2024	15/05
MediPharm Labs Q1 Gross Profit, Rise	15/05	MT
MediPharm Labs Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
MediPharm Labs Corp. Brief: Anticipates further improvement on profitability in 2024 with plans being implemented to improve Adjusted EBITDA by a further $1-$2 Million	15/05	MT
MediPharm Labs Corp. Brief: Revenue increased 67% to $9.8 Million during the three months ended March 31, 2024, versus revenue for the same quarter in 2023 of $5.8 Million	15/05	MT
MediPharm Labs Narrows Q4 Loss, Revenue Grows; Up 10.5%	27/03	MT
MediPharm Labs Narrows Q4 Loss, Revenue Grows	27/03	MT
Transcript : MediPharm Labs Corp., Q4 2023 Earnings Call, Mar 27, 2024	27/03
MediPharm Labs Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
MediPharm Labs Corp. Brief: Q4 Revenue $9.131 Million; Says Annual Revenue and Adjusted EBITDA Improve by 50%	27/03	MT
MediPharm Labs Offers Update on German Cannabis Legalization; Up Nearly 6%	25/03	MT
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023	25/03	MT
IM Cannabis Corp. Brief: Adds By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is Expected to deliver "Strong" growth	25/03	MT
IM Cannabis Corp. Brief: Says Expects "Accelerated Growth" in Germany from that Country's "Groundbreaking" Cannabis Legalization	25/03	MT
MediPharm Labs Offers Update on German Cannabis Legalization	25/03	MT
MediPharm Labs Corp. Brief: Says "Historic change is a significant positive step in removing the stigma related to medical cannabis"	25/03	MT
MediPharm Labs Corp. Brief: Providing Update on German Cannabis Legalization	25/03	MT
MediPharm Labs Provides Update on German Cannabis Legalization	25/03	CI
MediPharm Labs Corp. Says Achieved Pharmaceutical GMP Certification with Brazilian Health Authority	07/02	MT
MediPharm Labs Corp. Brief: Says Achieved Pharmaceutical GMP Certification with Brazilian Health Authority	07/02	MT
Transcript : MediPharm Labs Corp., Q3 2023 Earnings Call, Nov 14, 2023	14/11

Chart MediPharm Labs Corp.

Duration

Period

More charts

Company Profile

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for MediPharm Labs Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.075 CAD

Average target price

0.1 CAD

Spread / Average Target

+33.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
MEDIPHARM LABS CORP.	+15.38%	22.19M
DONG-E-E-JIAO CO.,LTD.	+26.93%	5.55B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-33.55%	3.52B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-3.74%	3.03B
TASLY PHARMACEUTICAL GROUP CO., LTD	-26.09%	2.59B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-10.93%	2.28B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.50%	1.88B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+41.84%	1.46B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-12.94%	1.43B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+47.62%	1.42B

Alternative Medicine